Insider Transactions in Q1 2021 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
17,727
-4.38%
|
$478,629
$27.46 P/Share
|
|
Mar 17
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.62%
|
$160,000
$16.23 P/Share
|
|
Feb 18
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,250
-3.46%
|
$35,000
$28.67 P/Share
|
|
Feb 17
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,250
-3.35%
|
$33,750
$27.35 P/Share
|
|
Feb 08
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.98%
|
$149,203
$31.58 P/Share
|
|
Feb 08
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,250
-6.53%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,250
-5.63%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,250
-5.68%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.86%
|
$34,875
$31.58 P/Share
|
|
Feb 08
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,125
-2.37%
|
$34,875
$31.58 P/Share
|
|
Feb 05
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.89%
|
$149,203
$31.41 P/Share
|
|
Feb 05
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,250
-6.13%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,250
-5.33%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,250
-5.38%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.83%
|
$34,875
$31.41 P/Share
|
|
Feb 05
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,125
-2.32%
|
$34,875
$31.41 P/Share
|
|
Feb 04
2021
|
Steve Aselage Director |
BUY
Bona fide gift
|
Indirect |
25,000
+50.0%
|
-
|
|
Feb 04
2021
|
Steve Aselage Director |
SELL
Bona fide gift
|
Direct |
25,000
-13.17%
|
-
|
|
Feb 03
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+9.51%
|
-
|
|
Feb 03
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.92%
|
-
|
|
Feb 03
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.63%
|
-
|
|
Feb 03
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+6.81%
|
-
|
|
Feb 03
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.71%
|
-
|
|
Feb 03
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+8.48%
|
-
|
|
Feb 03
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,406
-1.59%
|
$67,368
$28.91 P/Share
|
|
Feb 03
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-5.17%
|
$101,500
$28.91 P/Share
|
|
Feb 03
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
3,175
-3.94%
|
$88,900
$28.91 P/Share
|
|
Feb 03
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
3,625
-4.51%
|
$101,500
$28.91 P/Share
|
|
Feb 03
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,813
-1.99%
|
$50,764
$28.91 P/Share
|
|
Feb 03
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
563
-0.98%
|
$15,764
$28.91 P/Share
|
|
Feb 02
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
563
-0.97%
|
$16,890
$30.75 P/Share
|
|
Feb 02
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
25,000
-11.28%
|
$750,000
$30.75 P/Share
|
|
Feb 02
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.14%
|
$250,000
$10.09 P/Share
|
|
Feb 02
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-4.69%
|
$108,750
$30.75 P/Share
|
|
Feb 02
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
8,734
-2.76%
|
$262,020
$30.18 P/Share
|
|
Feb 02
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
3,175
-3.65%
|
$95,250
$30.75 P/Share
|
|
Feb 02
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
3,625
-4.14%
|
$108,750
$30.75 P/Share
|
|
Feb 02
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,813
-1.92%
|
$54,390
$30.75 P/Share
|
|
Jan 31
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+11.24%
|
-
|
|
Jan 31
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.57%
|
-
|
|
Jan 31
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.19%
|
-
|
|
Jan 31
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.08%
|
-
|
|
Jan 31
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+9.48%
|
-
|
|
Jan 21
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
57,260
+28.3%
|
-
|
|
Jan 21
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+30.32%
|
-
|
|
Jan 21
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+20.49%
|
-
|
|
Jan 21
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+27.75%
|
-
|
|
Jan 21
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.99%
|
-
|
|
Jan 21
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+27.48%
|
-
|
|
Jan 06
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,438
-3.77%
|
$92,826
$27.01 P/Share
|